Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Global Link Language Services, Inc.

25 Years of Language Excellence by Language Experts
We provide language solutions of clinical trial management and linguistic validation for Clinical Outcome Assessment with deep experience in a variety of areas regulatory affairs, medical devices, medical documentation, marketing communication, and informed consent forms.

This is a FREE LISTING on PMHUB

Below are full profiles from other companies in related areas

- PMLiVE

Atlas Translations Ltd

With Atlas Translations Ltd you get a service that is both personal and professional. This means that your message will be understood in the language and context you need it…

View Profile

Translation services

Streaming Well - Video For Healthcare

Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual stories and interactive experiences that connect with people.

View Profile

Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Medical communications, Medical education, Publishers, Translation services

Company Details

Global Link Language Services, Inc.
71 Commercial Street, Suite 218, Boston, MA, 02109, United States
8774516655
Contact Global Link Language Services, Inc.
Website

 Latest Content from PMHub 

Take the Multichannel Health Check

White Papers and Resources | October 9, 2014 | Blue Latitude Health

Complete the Multichannel Health Check to find out what type of marketer you are and receive expert advice on how to get to the next step.

How to prepare and execute a multichannel campaign

White Papers and Resources | October 6, 2014 | Blue Latitude Health

You may be familiar with digital marketing, however Multichannel Marketing is quite different.

Getting to grips with Russia’s healthcare market

White Papers and Resources | October 2, 2014 | Inizio

As a non-Russian, trying to understand the complexities of the multiple overlapping levels of Russia’s healthcare system can be baffling at times. Information is often inaccessible or data simply doesn't...

Pegasus shortlisted for ‘PM Society Digital Media Awards 2014’

Press Releases | September 5, 2014 | Inizio

Brighton-based independent healthcare specialist continues to showcase its digital expertise with shortlist nomination

Exploring MINT: Part 3 – Nigeria

White Papers and Resources | August 22, 2014 | Inizio

In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria.

3 Steps to Navigating Multichannel in Healthcare

White Papers and Resources | August 18, 2014 | Blue Latitude Health

You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign.

Exploring MINT: Part 2 – Indonesia

White Papers and Resources | August 12, 2014 | Inizio

In the second of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Indonesia, with...

Pegasus Wins ‘Consultancy of the Year’ at Communiqué Awards 2014

Press Releases | July 9, 2014 | Inizio

Pegasus, the UK’s leading independent health communications consultancy, picked up the much coveted ‘Consultancy of the Year’ award at last week’s Communiqué Awards 2014, fighting off stiff competition from the...

Free Thinking: Leveraging the ASEAN Market

White Papers and Resources | July 9, 2014 | Inizio

If you can only research one ASEAN market, which one do you choose?Our Free Thinking paper investigates the opportunities for pharma in ASEAN and outlines the factors you need to...

Free Thinking: Biosimilars: Friend or foe to healthcare?

White Papers and Resources | July 9, 2014 | Inizio

Our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.